Developing the EU’s first intestinal microbiota-based biologic
European Pharmaceutical Review
JUNE 12, 2024
The specific representation of these events differed between the treatments, highlighting potential differences in side effect profiles that should be explored in further studies. 2017; 55(7):1998-2008. Adverse events were relatively low in both groups (2.22 percent for MBK-01 and 4.26 percent for fidaxomicin). J Clin Microbiol.
Let's personalize your content